For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Genhance™ 680 is the acid form of VivoTag® 680 that can be used as a control or a fluorescent in vivo blood pool imaging agent. Upon dilution, a 1 mg package of Genhance 680 fluorescent imaging agent provides sufficient reagents for imaging approximately 20 mice (weighing ~25 grams each) when using the recommended dose of 0.05mg/100 µL 1xPBS.
The generally recommended procedure for in vivo imaging with Genhance 680 is administration via tail vein injection and imaging 30 minutes post injection.
|Fluorescent Agent Type||Vascular|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||Genhance|
|Unit Size||1 mg|
|Wave Length||680 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Genhance™ 680 is the acid form of VivoTag® 680 that can be used as a control or a fluorescent in vivo blood pool imaging agent.,Upon dilution, a 1mg package of Genhance 680 provides sufficient reagents for imaging approximately 20 mice (weighing ~25 grams each) when using the recommended dose of 0.05mg/100 µL 1xPBS.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.